It is my great honor to assume the role of Editor-in-Chief of Modern Pathology. For the last two decades, under the impressive leadership of Dr John Eble, our journal has made tremendous strides in expanding its scope to become one of the most prominent and widely read journals in the field. During Dr Eble's tenure, the number of submissions quadrupled (>1000 submissions in 2019) and an extraordinarily high impact factor was achived placing Modern Pathology 5th in rank among all Pathology journals. I bring to this position the scientific acumen from my more than 30 years of experience in Pathology. I am thrilled to utilize my extensive clinical, teaching, and program building experience to forge a path of responsiveness to the rapid evolution of our specialty. The revolutionary progress in human genomics that is reshaping our approach to diagnosis, prognostics, and therapeutics will continue to provide a major source of content to our readership. Disruptive disciplines that impact our practice will also be featured. Robust efforts will be made to seek original manuscripts on the emerging areas of predictive biomarkers for immunotherapy, the role of machine learning and artificial intelligence in digital pathology, and applied bioinformatics. I am confident that with this expanded focus Modern Pathology is ideally positioned to present these emerging frontiers and propagate these discoveries.
Aiming for diversity from across the globe, I have assembled a distinguished editorial leadership team of 16 experts spanning the various subspecialties of our discipline. Our editorial board of 152 members brings an unmatched depth of expertize in precision diagnostics, genomics, digital pathology, and computational sciences.
With an aim to improve the author experience, we have structured the peer review process to accelerate the timeline from submission to publication. Each submitted manuscript will receive a meticulous editorial pre-review that will assure prompt feedback to authors whose submissions are out of scope. Following this evaluation, our peer review target will be measured in days rather than weeks to months.
Junior pathologists and pathology trainees have embraced the various social media platforms in an unprecedented fashion, which is re energizing case and article sharing. Therefore a rigorous strategy to enhance Modern Pathology's social media footprint will be implemented with resources vested by the United States and Canadian Academy of Pathology (USCAP) and our Springer Nature publisher. These efforts will be orchestrated by a new dedicated Associate Editor for social media.
In keeping with the USCAP mission, Modern Pathology remains fully dedicated to present state of the art educational resources through expert reviews to our vast audience of pathology trainees, clinical and translational investigators, physician-scientists, and practicing pathologists. We also vigorously pursue opportunities to engage the next generation of pathology scholars in the peer review process. By inviting the brightest trainees and young faculty to gain valuable experience and insight into the publication of science, we hope to contribute to the future growth of our academic organization.
On behalf of our dedicated team, I look forward to serving all of our readers and contributing to the growth of Modern Pathology as the premier journal of our exciting and ever-evolving discipline.
